Supplementary Figure 1 from Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

Authors :: Joong-Won Park
Demetrios Manekas
Christine Baudelet
Ian Walters
Ho Yeong Lim
Blase N. Polite
Mary Mulcahy
Yoon-Koo Kang
Richard S. Finn
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: PDF file - 35K

Full Text Access

Tools